Doll Christian, Nack Claudia, Raguse Jan-Dirk, Stricker Andres, Duttenhoefer Fabian, Nelson Katja, Nahles Susanne
Department of Oral and Maxillofacial Surgery/Clinical Navigation, Campus Virchow-Clinic, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany,
Clin Oral Investig. 2015 Jul;19(6):1347-52. doi: 10.1007/s00784-014-1359-2. Epub 2014 Nov 23.
The purpose of this study was to evaluate the long-term survival rate and potential influencing factors of dental implants and implant-retained prostheses in oral cancer patients who had undergone surgical tumor resection.
In the present study, 157 patients (95 females and 62 males with a mean age of 53.7 years) with 830 implants were included. All patients were diagnosed with a malignant tumor in the oral cavity and had undergone ablative surgery. In 55 patients (292 implants), the surgical procedure was followed by an additional radiochemotherapy (RCT) before implant placement. Nicotine users who received RCT were excluded from this study. Patients were clinically examined every 6 or 12 months according to a standard procedure.
Of the 830 examined implants, 450 were placed in the maxilla and 380 in the mandible. A total of 65 implants were lost, 36 in the maxilla and 29 in the mandible; of these, 42 implants (65%) were documented as lost due to the patient's death. The mean observation period was 121 months. The cumulative survival rate was 94.9% at 3 years and 92.5% at 7 years. With an observation period up to 20 years, the cumulative survival rate remained constant after 11 years with 90.8%. Age, gender, and localization (maxilla/mandible) of implants did not show any influence on the survival of the implants. However, radiochemotherapy was determined as a significant factor influencing the survival rate.
The results of this study demonstrate that the survival rate of implants was significantly lower in oral cancer patients who had been treated by ablative surgery and additional radiochemotherapy than in patients without RCT. Since there is no significant difference in the mortality rate of patients with additional RCT compared to patients who underwent sole ablative surgery, the higher loss ratio is due to a late failure of osseointegration.
Dental implants in oral cancer patients who had been treated by ablative surgery show a high and steady cumulative survival rate after 11 years. Implant survival of patients with additional RCT is significantly lower. Non-smoking-irradiated patients seem to have a better implant survival.
本研究旨在评估接受肿瘤手术切除的口腔癌患者牙种植体及种植修复体的长期生存率和潜在影响因素。
本研究纳入了157例患者(95例女性,62例男性,平均年龄53.7岁),共植入830颗种植体。所有患者均被诊断为口腔恶性肿瘤并接受了切除手术。55例患者(292颗种植体)在手术治疗后于种植体植入前接受了额外的放化疗(RCT)。接受RCT的吸烟者被排除在本研究之外。按照标准程序每6或12个月对患者进行临床检查。
在检查的830颗种植体中,450颗植入上颌骨,380颗植入下颌骨。共有65颗种植体丢失,上颌骨36颗,下颌骨29颗;其中42颗种植体(65%)记录为因患者死亡而丢失。平均观察期为121个月。3年时的累积生存率为94.9%,7年时为92.5%。观察期长达20年,11年后累积生存率保持在90.8%不变。种植体的年龄、性别和植入部位(上颌骨/下颌骨)对种植体的存活无任何影响。然而,放化疗被确定为影响生存率的一个重要因素。
本研究结果表明,接受切除手术及额外放化疗的口腔癌患者种植体的生存率显著低于未接受RCT的患者。由于接受额外RCT的患者与仅接受切除手术的患者死亡率无显著差异,较高的丢失率是由于骨结合的晚期失败。
接受切除手术治疗的口腔癌患者的牙种植体在11年后显示出较高且稳定的累积生存率。接受额外RCT的患者种植体存活率显著较低。非吸烟且未接受放疗的患者似乎种植体存活率更高。